Recent clinical investigations have highlighted epicardial adipose tissue volume as a pivotal biomarker for assessing cardiorenal risk in patients with hypertension. Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the pericardium. While both EAT volume and density are measurable via computerized tomography, current evidence suggests that volume offers superior predictive value. Research published in 2026 clarifies how these adiposity markers influence heart and kidney health in hypertensive populations.

Predictive Value of Epicardial Adipose Tissue Volume

The study compared 156 hypertensive individuals with 101 healthy controls using coronary computerized tomography angiography. Specifically, patients with hypertension demonstrated significantly higher epicardial adipose tissue volume compared to their normotensive counterparts. In contrast, researchers observed no substantial difference in EAT density between the two groups. Statistical analyses revealed that EAT volume correlates strongly with critical markers such as left ventricular mass index and the Renin-Angiotensin System Index. Consequently, these findings indicate that the quantity of fat surrounding the heart directly impacts structural cardiac changes.

Clinical Significance of Epicardial Adipose Tissue Volume

Mediation analysis further illustrates the complex relationship between hypertension and cardiorenal dysfunction. Epicardial adipose tissue volume acts as a significant mediator, bridging the gap between elevated blood pressure and end-organ damage. Moreover, managing EAT through lifestyle or pharmacological interventions could potentially mitigate the risk of heart failure. Clinicians should consider EAT volume as a standard metric in cardiac imaging for hypertensive patients to refine risk stratification.

Furthermore, the data suggests that the association of EAT volume with complications remains robust after adjusting for traditional risk factors. This independence confirms that localized adiposity exerts unique paracrine effects on the heart and kidneys. Therefore, prioritizing volume measurements over density provides a more accurate reflection of a patient's clinical trajectory. However, further longitudinal studies are needed to confirm these causal pathways in diverse populations.

Frequently Asked Questions

How does EAT volume specifically affect the heart?

High EAT volume releases proinflammatory cytokines directly into the myocardium. This paracrine activity leads to structural remodeling, such as left ventricular hypertrophy and myocardial fibrosis, which are common in hypertensive patients.

Why is EAT volume a better marker than EAT density in hypertension?

While EAT density reflects the metabolic state of the tissue, EAT volume represents the total burden of visceral fat. In hypertensive patients, the absolute amount of fat appears more closely linked to mechanical and hormonal complications.

Can EAT volume be reduced to improve outcomes?

Yes, intensive lifestyle modifications and certain medications, such as SGLT2 inhibitors, have shown promise in reducing EAT volume. Lowering this fat depot may help decrease the risk of cardiorenal complications over time.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Wu HX et al. Epicardial adipose tissue volume outperforms density in association with cardiorenal complications in hypertensive patients. Lipids Health Dis. 2026 Feb 12. doi: 10.1186/s12944-026-02873-x. PMID: 41673673.

Iacobellis G. Epicardial adipose tissue: from radiology to clinical practice. Nat Rev Endocrinol. 2022;18(10):593-605.

Bertaso AG, Bertol D, Duncan BB, Foppa M. Epicardial Fat: Review of Proper Measurement and Clinical Significance. Arq Bras Cardiol. 2013;101(1):88-95.